


DOCKET NO.: ADOL-0497
Application No.: 09/796,450
Office Action Dated: March 22, 2004

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Kruse et al.

Confirmation No.: **4357**

Application No.: **09/796,450**

Group Art Unit: **1617**

Filing Date: **January 26, 2001**

Examiner: **S. Wang**

For: **KAPPA AGONIST COMPOUNDS, PHARMACEUTICAL
FORMULATIONS AND METHOD OF PREVENTION AND TREATMENT
OF PRURITUS THEREWITH**

DATE OF DEPOSIT: July 14, 2004

I HEREBY CERTIFY THAT THIS PAPER IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID,
ON THE DATE INDICATED ABOVE AND IS
ADDRESSED TO THE COMMISSIONER FOR PATENTS,
P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

TYPED NAME: David A. Cherry
REGISTRATION NO.: 35,099

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

REPLY PURSUANT TO 37 CFR § 1.111

In response to the Official Action dated **March 22, 2004**, reconsideration is respectfully requested in view of the amendments and/or remarks as indicated below:

- ☒ **Amendments to the Specification** begin on page 2 of this paper.
- ☒ **Amendments to the Claims** are reflected in the listing of the claims which begins on page 3 of this paper.
- ☐ **Amendments to the Drawings** begin on page _____ of this paper and include an attached replacement sheet.
- ☒ **Remarks** begin on page 5 of this paper.